retatrutide phase 2 trial obesity triple agonist hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide for Obesity: Phase 2

*This compound is unstable in solutions, freshly prepared is recommended

Five-point MACE included nonfatal ischemic stroke, nonfatal MI, all-cause death, hospitalization for unstable angina (primary diagnosis in the inpatient setting using ICD-10-CM code I20.0), and hospitalization for heart failure (primary diagnosis in the inpatient setting using ICD-10-CM code I50)

The authors thank AI + High Performance Computing Center of ZJU-ICI for their support in molecular dynamics simulations

Potent Anti-Inflammatory Properties Inflammation is a common factor in many chronic conditions, from arthritis to digestive disorders

These methods might be safer and more suitable for some individuals

The elevations in serum cholesterol, TG and LDL levels observed in this study were in agreement with those reported in several studies (Binmowyna Alfaris, Almnaizel, Alsayadi, & Abdo al sanea, 2021